DDInter1886 DDInter1930
Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.
Vibegron is a potent, selective beta-3 adrenergic receptor (β3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder, a condition associated with distressing symptoms of urge urinary incontinence, urgency, and urinary frequency, and reduced quality of life of patients. On December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. Vibegron is the second beta-3 adrenergic agonist approved for the treatment of overactive bladder following [mirabegron], which was approved in 2012. Unlike mirabegron, vibegron is less likely to be associated with drug-drug interactions involving the CYP3A4, 2D6, or 2C9 enzymes.
Trospium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Trospium {u} (Compound) resembles {v} (Compound) Homatropine Methylbromide
Trospium {u} (Compound) binds {v} (Gene) CHRM3
Trospium {u} (Compound) is included by {v} (Pharmacologic Class) Cholinergic Muscarinic Antagonists
Trospium {u} (Compound) causes {v} (Side Effect) Delirium
Trospium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Polythiazide
Trospium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Botulinum toxin type A
Trospium {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Trospium {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darifenacin
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Trospium (Compound) resembles Homatropine Methylbromide (Compound)
Trospium (Compound) binds CHRM3 (Gene)
Trospium (Compound) is included by Cholinergic Muscarinic Antagonists (Pharmacologic Class)
Trospium (Compound) causes Delirium (Side Effect)
Trospium may cause a minor interaction that can limit clinical effects when taken with Polythiazide
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Botulinum toxin type A
Trospium may lead to a major life threatening interaction when taken with Potassium chloride
Trospium (Compound) resembles Darifenacin (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin